Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AU-007 in Advanced Solid Tumors
NCT05267626Phase 2Recruiting
- Sponsor
- Aulos Bioscience
- Start
- Apr 2022
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of imneskibart in solid tumor, melanoma, non-small cell lung cancer (NSCLC), sponsored by Aulos Bioscience. Started Apr 2022; status: recruiting.
02
Drugs
imneskibart
03
Conditions
solid tumormelanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05267626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05267626.